{
    "clinical_study": {
        "@rank": "121119", 
        "arm_group": {
            "arm_group_label": "RoActemra/Actemra", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, single-arm study will evaluate the efficacy and safety of subcutaneously\n      administered RoActemra/Actemra (tocilizumab) in monotherapy and/or in combination with\n      methotrexate and other non-biologic DMARDs in patients with active rheumatoid arthritis who\n      are na\u00efve to RoActemra/Actemra. Patients will receive RoActemra/Actemra 162 mg\n      subcutaneously weekly for 24 weeks. Patients who complete the core study achieving at least\n      a moderate EULAR response at Week 24 may enter the extension phase and receive\n      RoActemra/Actemra for a further 28 weeks at the most."
        }, 
        "brief_title": "TOSCARA Study: A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Na\u00efve to RoActemra/Actemra Treatment", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Active moderate to severe rheumatoid arthritis according to the revised (1987) ACR\n             criteria or EULAR/ACR (2010) criteria\n\n          -  Inadequate response or intolerant to previous therapy with two or more non-biologic\n             disease-modifying anti-rheumatic drugs (DMARDs), one of which is methotrexate,\n             administered in an optimal way during at least 3 months; eligible patients may also\n             be inadequate responders to a maximum of one biologic DMARD\n\n          -  Oral corticosteroids (</= 10 mg/day prednisolone or equivalent) and non-steroidal\n             anti-inflammatory drugs (NSAIDs; up to the recommended dose) are permitted if on\n             stable dose regimen for >/= 4 weeks prior to baseline\n\n          -  Permitted DMARDs are allowed if at stable dose for at least 4 weeks prior to baseline\n\n          -  Receiving treatment on an outpatient basis, not including RoActemra/Actemra\n\n          -  Females of childbearing potential and males with female partners of childbearing\n             potential must agree to use reliable means of contraception as defined by protocol\n\n        Exclusion Criteria:\n\n          -  Major surgery (including joint surgery) within 8 weeks prior to screening or planned\n             major surgery within 6 months following baseline or during LTE period\n\n          -  Rheumatic autoimmune disease other than rheumatoid arthritis\n\n          -  Functional Class IV as defined by the ACR Classification of Functional Status in\n             Rheumatoid Arthritis\n\n          -  Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of\n             16\n\n          -  Prior history of or current inflammatory joint disease other than RA\n\n          -  Exposure to tocilizumab (intravenous or subcutaneous) at any time prior to baseline\n\n          -  Treatment with any investigational agent within 4 weeks (or 5 half-lives of the\n             investigational drug, whichever is longer) of screening\n\n          -  Intraarticular or parenteral corticosteroids within 4 weeks prior to baseline\n\n          -  History of severe allergic or anaphylactic reactions to human, humanized or murine\n             monoclonal antibodies\n\n          -  Evidence of serious concomitant disease or disorder\n\n          -  Known active current or history of recurrent infection\n\n          -  Any major episode of infection requiring hospitalization or treatment with IV\n             antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of\n             screening\n\n          -  Active TB requiring treatment within the previous 3 years\n\n          -  Positive for hepatitis B or hepatitis C\n\n          -  Primary or secondary immunodeficiency (history of or currently active)\n\n          -  Pregnant or lactating women\n\n          -  Neuropathies or other conditions that might interfere with pain evaluation\n\n          -  Inadequate hematologic, renal or liver function"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02031471", 
            "org_study_id": "ML28701"
        }, 
        "intervention": {
            "arm_group_label": "RoActemra/Actemra", 
            "description": "162 mg subcutaneously weekly", 
            "intervention_name": "tocilizumab [RoActemra/Actemra]", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "zip": "9300"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Assebroek", 
                        "country": "Belgium", 
                        "zip": "8310"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bonheiden", 
                        "country": "Belgium", 
                        "zip": "2820"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bouge", 
                        "country": "Belgium", 
                        "zip": "5004"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "zip": "1070"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "zip": "9000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gilly", 
                        "country": "Belgium", 
                        "zip": "6060"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gosselies", 
                        "country": "Belgium", 
                        "zip": "6041"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Haine-St-Paul", 
                        "country": "Belgium", 
                        "zip": "7100"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ixelles", 
                        "country": "Belgium", 
                        "zip": "1050"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Liege", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roeselare", 
                        "country": "Belgium", 
                        "zip": "8800"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sijsele-Damme", 
                        "country": "Belgium", 
                        "zip": "8340"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sint-Niklaas", 
                        "country": "Belgium", 
                        "zip": "9100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wilrijk", 
                        "country": "Belgium", 
                        "zip": "2610"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Luxembourg", 
                        "country": "Luxembourg", 
                        "zip": "2763"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Luxembourg"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Single Arm Study to Evaluate the Efficacy and Safety and Tolerability of Tocilizumab (TCZ) Subcutaneous in TCZ-na\u00efve Patients With Active Rheumatoid Arthritis", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML28701 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Belgium: Agence f\u00e9d\u00e9rale des m\u00e9dicaments et produits de sant\u00e9"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in Disease Activity Score 28 - erythrocyte sedimentation rate (DAS28-ESR) score", 
            "safety_issue": "No", 
            "time_frame": "from baseline to Week 24"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02031471"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in American College of Rheumatology (ACR) response scores", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in European League Against Rheumatism (EULAR) response criteria", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in Simplified Disease Activity Index (SDAI)/Clinical Disease Activity Index (CDAI)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Change in total tender/swollen joint count (TJC/SJC)", 
                "safety_issue": "No", 
                "time_frame": "from baseline to Week 24"
            }, 
            {
                "measure": "Proportion of patients with corticosteroid dose reduction/discontinuation", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients achieving low disease activity, defined as DAS28 </= 3.2, CDAI </= 10.0, SDAI </= 11.0", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients achieving remission, defined as DAS28 </= 2.6, CDAI </= 2.8, SDAI </=3.3", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients achieving a clinically significant improvement in DAS28 (reduction of at least 1.2 units)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Percentage of patients with major or minor improvement in SDAI/CDAI", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 60 weeks"
            }, 
            {
                "measure": "Safety: Incidence of anti-tocilizumab antibodies", 
                "safety_issue": "No", 
                "time_frame": "up to 60 weeks"
            }, 
            {
                "measure": "Patient reported quality of life (Questionnaires: HAQ-DI, FACIT-F, PSQI, AIMS-SF, TSQM, RA-WIS, Visual Analogue Scales)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}